Nanoparticles coated in an antigen stick to red blood cells strongly enough to resist being sheared off in the lungs, allowing them to reach the spleen and be passed off to immune cells, initiating an antigen-specific immune response. Credit: Wyss Institute at Harvard University
New platform technology uses red blood cells to generate targeted immune responses in mice
Red blood cells do more than shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens on their surfaces, neutralizing them, and presenting them to immune cells in the spleen and liver.
A team of researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) has harnessed this innate ability to build a platform technology that uses red blood cells to deliver antigens to antigen-presenting cells (APCs) in the spleen, generating an immune response.
This approach successfully slowed the growth of cancerous tumors in mice, and could also be used as a biocompatible adjuvant for a variety of vaccines. The technology, called Erythrocyte-Driven Immune Targeting (EDIT), is reported this week in PNAS.
“The spleen is one of the best organs in the body to target when generating an immune response, because it is one of the few organs where red and white blood cells naturally interact,” said senior author Samir Mitragotri, a Wyss Core Faculty member who is also the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at SEAS. “Red blood cells’ innate ability to transfer attached pathogens to immune cells has only recently been discovered, and this study unlocks the door to an exciting array of future developments in the field of using human cells for disease treatment and prevention.”
A ‘check me out’ signal
Using red blood cells as delivery vehicles for drugs is not a new idea, but the vast majority of existing technologies target the lungs, because their dense network of capillaries causes cargoes to shear off of red blood cells as they squeeze through the tiny vessels. Mitragotri’s research team first needed to figure out how to get antigens to stick to red blood cells strongly enough to resist shearing off and reach the spleen.
They coated polystyrene nanoparticles with ovalbumin, an antigenic protein known to cause a mild immune response, then incubated them with mouse red blood cells. The ratio of 300 nanoparticles per blood cell resulted in the greatest number of nanoparticles bound to the cells, retention of about 80 percent of the nanoparticles when the cells were exposed to the shear stress found in lung capillaries, and moderate expression of a lipid molecule called phosphatidyl serine (PS) on the cells’ membranes.
“A high level of PS on red blood cells is essentially an ‘eat me’ signal that causes them to be digested by the spleen when they are stressed or damaged, which we wanted to avoid. We hoped that a lower amount of PS would instead temporarily signal ‘check me out’ to the spleen’s APCs, which would then take up the red blood cells’ antigen-coated nanoparticles without the cells themselves getting destroyed,” said Anvay Ukidve, a graduate student in the Mitragotri lab and co-first author of the paper.
To test that hypothesis, the team injected red blood cells coated with their nanoparticles into mice, then tracked where they accumulated in their bodies. Twenty minutes after injection, more than 99 percent of the nanoparticles had been cleared from the animals’ blood, and more nanoparticles were present in their spleens than their lungs.
The higher nanoparticle accumulation in the spleen persisted for up to 24 hours and the number of EDIT red blood cells in the circulation remained unchanged, showing that the red blood cells had successfully delivered their cargoes to the spleen without being destroyed.
Effective, adjuvant-free vaccines
Having confirmed that their nanoparticles were successfully delivered to the spleen in vivo, the researchers next evaluated whether the antigens on the nanoparticles’ surfaces induced an immune response.
Mice were injected with EDIT once a week for three weeks, and then their spleen cells were analyzed. Treated mice displayed eight-fold and 2.2-fold more T cells displaying the delivered ovalbumin antigen than mice that were given “free” nanoparticles or were untreated, respectively. Mice treated with EDIT also produced more antibodies against ovalbumin in their blood than either of the other groups of mice.
To see if these EDIT-induced immune responses could potentially prevent or treat disease, the team repeated their three-week prophylactic injection of EDIT into mice, then inoculated them with lymphoma cells that expressed ovalbumin on their surfaces.
The mice that received EDIT had about three-fold slower tumor growth compared with the control group and the group that received free nanoparticles, and had lower numbers of viable cancerous cells. This outcome significantly increased the window of time during which the tumor could be treated before the mice succumbed to the disease.
“EDIT essentially is an adjuvant-free vaccine platform. Part of the reason why vaccine development today takes so long is that foreign adjuvants delivered along with an antigen have to go through a full clinical safety trial for each new vaccine,” said Zongmin Zhao, a postdoctoral fellow in the Mitragotri lab and co-first author of the paper. “Red blood cells have been safely transfused into patients for centuries, and their ability to enhance immune responses could make them a safe alternative to foreign adjuvants, increasing the efficacy of vaccines and speed of vaccine creation.”
The team is continuing to work on understanding exactly how an immune response that is specific to the antigen presented by EDIT is generated by the spleen’s APCs, and plans to test it with other antigens beyond ovalbumin. They hope to use this additional insight to drive their pursuit of the optimal clinical setting(s) for the technology.
“The human body is a treasure trove of elegant solutions to healthcare problems, and while medicine has come a long way in understanding those mechanisms, we are still in the early stages of being able to harness them to improve the length and quality of human life. This research is an exciting step forward toward that goal, and could dramatically change how immune responses are modulated in patients,” said the Wyss Institute’s Founding Director Donald Ingber, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and professor of bioengineering at SEAS.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Erythrocyte-Driven Immune Targeting
- CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcripton August 8, 2020 at 12:59 am
Q2 2020 Earnings Conference Call August 06, 2020 5:30 PM ET Company Participants Christopher Keenan – Vice President of Investor Relations Sean McCarthy – President, Chief Executive Officer and ...
- Recursion Posts Immune Mapping and Drug Discovery Resource and Releases New Image Datasetson August 4, 2020 at 12:13 pm
These high dimensional representations of complex immune behavior enabled Recursion to conduct high-throughput screens of nearly 100,000 potential drug starting points, and to predict the target of ...
- ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lungon August 3, 2020 at 8:16 am
Pathological group 2 innate lymphoid cells (ILC2s) have mainly been implicated in allergy. Halim and colleagues demonstrate that ILC2s orchestrate a prometastatic pathway via the recruitment of ...
- AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegenerationon August 3, 2020 at 4:15 am
First-in-class TDP-43 antibodydeveloped using SurpraAntigen™ platformThe only TDP-43 antibody with reported in vivo activityLAUSANNE, ...
- Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFNon July 28, 2020 at 4:15 am
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that its novel drug candidate, nipocalimab, has received ...
Go deeper with Google Headlines on:
Erythrocyte-Driven Immune Targeting
Go deeper with Bing News on:
- This Company Boasted to Trump About Its Covid-19 Vaccine. Experts Are Skeptical.on August 9, 2020 at 4:06 am
Inovio, a Pennsylvania biotech company, has spent years claiming to be on the cusp of important vaccines. It has never brought one to market.
- Brazilian Billionaire Lemann Leads Initiative to Build COVID-19 Vaccine Factoryon August 8, 2020 at 5:43 pm
Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical ...
- Dr. Fauci just made it easy to understand why coronavirus vaccines are so promisingon August 8, 2020 at 12:05 pm
Dr. Anthony Fauci gave a new update on coronavirus vaccine research and trials, explaining why he remains cautiously optimistic about COVID-19 vaccine research. The health expert compared COVID-19 ...
- Fauci Cautions Odds A Coronavirus Vaccine Will Have High-Efficacy Are 'Extremely Slim'on August 8, 2020 at 9:16 am
Fauci said even after a vaccine is deemed safe for use, the public should continue employing practices that help prevent the spread of coronavirus like washing hands and wearing face masks.
- New clues on virus reproduction mystery; non-COVID vaccines may helpon August 7, 2020 at 11:32 am
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.